TRENDING :  Market Movers  |  Top 50   AAPL (-0.23%)    FB (-0.89%)    KO (-0.77%)    AMZN (-0.91%)    UGAZ (4.96%)    VXXB (-3.5%)    MGM (3.07%)    MDB (1.02%)    KRE (2.17%)    AMD (2.38%)    ABMD (1.19%)    AA (0.25%)    IVC (12.08%)    HTGM (2.18%)    GOOS (-2.76%)    GH (4.51%)    GEVO (1.66%)    FUV (-31.27%)    FCEL (12.84%)    DIS (1.75%)    DGAZ (-4.98%)    CRON (2.26%)    CRM (-0.27%)    CGC (3.13%)    CAT (2.7%)

 INCY - Incyte Corporation

$84.15 [0.74][0.88%]

Next Earnings



Trade Idea »


Quarterly Rating Chart


1=Strong Buy, 2=Buy, 3=Hold, 4=Underperform, 5=Sell
Price Targets
High $82.00
Low $82.00
Average $82.00
Current $84.15

CompanyAnalyst NamePT ActionActionRatingTargetDate
*Last 90 days


Service NameTrader NamePosition TypeTarget %Target PriceTarget Date Issue Date
Big PortfolioTraderCZSubscribe12.45 %Subscribe09/23/1809/23/17View

This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.



No recommendations found.


Incyte (INCY) Q4 2018 Earnings Conference Call Transcript

Image source The Motley Fool Incyte NASDAQ INCY Q4 2018 Earnings Conference Call Feb 14 2019 8 00 a m ET Contents Prepared Remarks Questions and Answers Call Participants Prepared Remarks Operator Greetings

Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat

Incyte Corporation INCY reported mixed results for the fourth quarter of 2018 wherein earnings missed expectations while revenues beat the same The company reported earnings of 40 cents per share which missed the Zacks Consensus Estimate of 43 cents but was up from 2 cents reported in

Incyte (INCY) Q4 Earnings Lag Estimates

Incyte INCY came out with quarterly earnings of 0 40 per share missing the Zacks Consensus Estimate of 0 43 per share This compares to earnings of 0 02 per share a year ago These figures are adjusted for non recurring items This quarterly report represents an earnings surprise of 6

Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars

It was a busy week for the biotech sector Apart from earnings regular pipeline updates and data read outs were also in the news Key among them include bigwig Gilead Sciences phase III study on liver disease drug fails while Regeneron cuts the price of its PCSK9 inhibitor to make it

Pre-Market Earnings Report for February 14, 2019 : KO, DUK, CME, WM, ZTS, IQV, CCEP, PPL, TU, AZN, INCY, AEE

The following companies are expected to repor t earnings prior to market open on 02 14 2019 Visit our Earnings Calendar for a full list of expected earnings releases Coca Cola Company KO is reporting for the quarter ending December 31 2018 The

Notable ETF Inflow Detected - QQEW, I, CELG, INCY

Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the First Trust NASDAQ 100 Equal Weighted Index Fund Symbol QQEW where we have detected an approximate 90 7 million dollar inflow that s a 16 4 increase week

Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer

Merck amp Co Inc 160 MRK announced that the FDA has granted a priority review to yet another supplemental biologics license application sBLA for its PD L1 inhibitor Keytruda With the latest sBLA filing Merck is looking to get Keytruda approved for the first line treatment of featured highlights include: Incyte, First Majestic, Mattel and U.S. Silica

For Immediate Release Chicago IL February 12 2019 Stocks in this week s article are Incyte Corp INCY First Majestic Silver Corp AG Mattel Inc MAT and U S Silica Holdings Inc SLCA 4 Toxic Stocks to Abandon or Sell Short for Solid Gains

Is a Disappointment in Store for Incyte (INCY) Q4 Earnings?

Incyte Corporation INCY is scheduled to report fourth quarter 2018 results on Feb 14 before the market opens In the las t report ed quarter the company missed estimates by 5 0 Incyte s earnings track record has been disappointing so far Over the last four quarters the company

4 Toxic Stocks to Abandon or Sell Short for Solid Gains

Proper identification of rightly priced stocks is the key to successful investing However in reality overpriced toxic stocks and the rightly priced stocks are intertwined in such a manner that it is difficult to distinguish between the two Usually overhyped toxic stocks are vulnerable

Why Incyte Stock Gained 27% in January

What happened Pharmaceutical specialist Incyte NASDAQ INCY shot higher in a good month for the broader market as the stock gained 27 in January compared with an 8 spike in the S amp P 500 according to data provided by S amp P Global Market Intelligence The

How The Parts Add Up: QQQ Headed For $186

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the

Incyte Down as FDA Extends Review Period of Jakafi for GVHD

Shares of Incyte Corporation INCY declined 1 9 after the FDA extended the review period of the supplemental New Drug Application sNDA for Jakafi to treat patients with acute graft versus host disease GVHD who have had an inadequate response to corticosteroids The sNDA for the treatment

Lilly/Incyte's Olumiant Meets Endpoint in Eczema Studies

Eli Lilly and Company LLY and Incyte Corporation INCY announced positive top line data from two late stage studies evaluating their oral JAK inhibitor Olumiant baricitinib as monotherapy for moderate to severe atopic dermatitis AD a type of eczema Data from the phase III

Lilly : Baricitinib Meets Primary Endpoint In BREEZE-AD1 And BREEZE-AD2

Lilly : Baricitinib Meets Primary Endpoint In BREEZE-AD1 And BREEZE-AD2

Biotech Stocks Facing FDA Decision In February

Biotech Stocks Facing FDA Decision In February

First Week of September 20th Options Trading For Incyte (INCY)

Investors in Incyte Corporation Symbol INCY saw new options begin trading this week for the September 20th expiration One of the key data points that goes into the price an option buyer is willing to pay is the time value so with 234 days until expiration the newly trading